Economic burden of relapsed/refractory diffuse large B-cell non-Hodgkin's lymphoma (DLBCL): A review of the literature.

e18564 Background: The addition of rituximab to standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) has been shown to be cost-effective. With demonstrated clinic...